To evaluate the efficacy and the safety profile of Rhubarb and alpha-Keto amino acid supplementation on patients of Chronic kidney disease.

Comparative evaluation of efficacy and safety profile of Rhubarb and alpha-Keto analogue of amino acid supplementation on patients of Chronic Kidney Disease.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/09/002947

Enrollment

100

Registered

2012-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic kidney disease

Interventions

Intervention1: Rhubarb,alpha Keto analogue of essential amino acid: GROUP-1:-conservative management GROUP-2:-conservative management + Tab.Rhubarb GROUP-3:-conservative management + Tab.alpha-Keto

Eligibility

Inclusion criteria

Inclusion criteria: •Chronic kidney disease of different etiology, before ESRD. •Patient not on dialysis.

Exclusion criteria

Exclusion criteria: •Pregnancy •Acute infection •Psychotic patient •Critically ill patient •HIV/HBsAg/Anti-HCV and immunocompromised patient. •Severe Renal pathology such as malignancy

Design outcomes

Primary

Measure	Time frame
1.Haemogram 2.Urine- Routine & Microscopic 3.Blood Glucose 4.Total Urine Protein(TUP) 5.Blood Urea 6.Serum Creatinine 7.Urine Creatinine Timepoint: Pre-dose and after 1st 2nd 3rd month after starting dosing	—

Secondary

Measure	Time frame
1.USG-Both kidneys 2.Chest X-ray( PA VIEW) Timepoint: Pre-dose and after 3 month post-dose.	—

Countries

India

Contacts

Public ContactDr IRFAN AHMAD KHAN

J.N. MEDICAL COLLEGE, A.M.U.

naseer_bettiah@yahoo.co.in9412596898

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026